Geoffrey E. Harris is Director at CANCER GENETICS, INC (CGIX). They have made 7 open-market trades across 3 companies since 2015, most recently 2023-01-17.
CIK 0001611395
6 open-market purchases totalling $115K since 2015, against 1 sale. Across 6 scored buys the stock is up 15.5% at ninety days, and 10.5 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 50% | 83% |
| Avg Move | -8.7% | -1.1% | +15.5% |
| Alpha | -8.6% | -3.8% | +10.5% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VYNT | SELL | 2022-11-18 | 2022-11-22 | $1.33 | $1K | +4.1% | -33.6% | -37.7% |
| CGIX | BUY | 2019-01-14 | 2019-01-16 | $0.23 | $23K | -7.2% | -7.5% | -7.9% |
| MYND | BUY | 2017-12-05 | 2017-12-07 | $3.81 | $17K | -6.6% | -2.9% | +11.8% |
| CGIX | BUY | 2017-05-16 | 2017-05-16 | $3.75 | $9K | +5.3% | +1.3% | +4.0% |
| CGIX | BUY | 2016-12-14 | 2016-12-14 | $1.50 | $4K | -6.9% | +17.2% | +48.3% |
| CGIX | BUY | 2016-11-14 | 2016-11-16 | $1.55 | $8K | -3.0% | -15.2% | +36.4% |
| CGIX | BUY | 2015-05-14 | 2015-05-18 | $10.79 | $54K | -33.9% | +0.6% | +0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| — |
| Total | $627K |
Shares reported on the most recent Form 4, priced at the 2023-01-19 close. 4 holdings could not be priced and are excluded from the total.